同步放疗联合奈达铂、紫杉醇治疗宫颈癌的临床分析  

Clinical analysis of concurrent radiotherapy combined with Nedaplatin and Paclitaxel for cervical cancer

作　　者：居文惠[1] 郑晓丹[1] 李晖[1] 刘华[1] 边疆[1] 

机构地区：[1]华中科技大学同济医学院附属荆州医院妇产科,湖北荆州434020

出　　处：《局解手术学杂志》2011年第6期662-664,共3页Journal of Regional Anatomy and Operative Surgery

摘　　要：目的研究分析同步放疗联合奈达铂、紫杉醇治疗宫颈癌的临床效果。方法临床选择64例宫颈癌患者随机分成两组,每组32例,对照组患者给予单纯放疗治疗,而研究组在对照组治疗的基础上同时给予奈达铂、紫杉醇治疗。治疗后观察分析两组患者的相关临床资料情况。结果治疗3个月后,对照组与研究组的总有效率分别为31.25%和75%,两组之间具有统计学差异(P<0.05)。随访1年,对照组的总生存率(68.75%)、无远处转移生存率(62.5%)及无局部复发率(62.5%),与研究组的总生存率(90.63%)、无远处转移生存率(87.5%)及无局部复发率(81.25%)比较,均具有统计学差异(P<0.05)。两组患者均出现了不同程度的不良反应,但在予以相应的对症支持治疗后好转。结论同步放疗联合奈达铂、紫杉醇治疗宫颈癌不仅疗效显著,而且具有一定的安全性。Objective To investigate the clinical efficacy of concurrent radiotherapy combined with Nedaplatin and Paclitaxel for cervical cancer.Methods Totally 64 patients with cervical cancer were retrospectively reviewed and randomly divided into control group and study group.The patients in control group were given concurrent radiotherapy while those in study group were treated with concurrent radiotherapy plus Nedaplatin and Paclitaxel.The clinical data of the two groups were compared.Results There were significant differences in the total effective rate between control group and study group,31.25% vs.75%（P〈0.05）.Meanwhile,there were significant differences in the overall survival rate,distant metastasis-free survival rate and non-local recurrence rate between control group and study group in the one year＇s follow-up（P〈0.05）,68.75%,62.5%,62.5% in control group and 90.63%,87.5%,81.25% in study group respectively.Adverse reactions were occurred in both groups and the manifestations of anorexia,fatigue,neutropenia and hemoglobin in study group were more obvious than those in control group（P〈0.05）.Meanwhile,the adverse reactions were meliorated after supportive treatment.ConclusionThe therapy of concurrent radiotherapy plus Nedaplatin and Paclitaxel is not only effective but also safe for cervical cancer.

关 键 词：宫颈癌 化疗 放疗 奈达铂 紫杉醇 

分 类 号：R737.33[医药卫生—肿瘤]